PCSA Stock Price, Processa Pharmaceuticals, . Quote, Chart

Market Summary

USD1.93-0.07

Delayed

-3.50%

PCSA Stock Price

View Fullscreen

PCSA RSI Chart

PCSA Valuation

Market Cap

5.5M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

270.56

EV/EBITDA

0.31

Price/Free Cashflow

-0.69

PCSA Price/Sales (Trailing)

PCSA Profitability

EBT Margin

-49428.98%

Return on Equity

-110.61%

Return on Assets

-98.8%

Free Cashflow Yield

-144.16%

PCSA Fundamentals

PCSA Revenue

Revenue (TTM)

22.5K

PCSA Earnings

Earnings (TTM)

-9.8M

Earnings Growth (Yr)

32.21%

Earnings Growth (Qtr)

-13.37%

Breaking Down PCSA Revenue

Last 7 days

-7.7%

Last 30 days

16.3%

Last 90 days

-22.2%

Trailing 12 Months

-85.4%

How does PCSA drawdown profile look like?

PCSA Financial Health

Current Ratio

9.7

PCSA Investor Care

Shares Dilution (1Y)

133.01%

Diluted EPS (TTM)

-6.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	0
2016	80.7K	80.7K	22.5K	0
2015	1.5M	1.4M	1.4M	113.4K
2014	391.7K	762.1K	1.1M	1.5M
2013	149.4K	106.7K	64.0K	21.3K
2012	0	0	0	192.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Processa Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	young david	bought	51,525	2.4536	21,000	pres. research & development
Feb 06, 2024	young david	bought	50,504	2.5252	20,000	pres. research & development
Feb 01, 2024	lin patrick	bought	3,600	2.4	1,500	chief business - strategy off
Jan 31, 2024	lin patrick	bought	5,925	2.37	2,500	chief business - strategy off
Jan 30, 2024	yorke justin w	bought	21,544	2.693	8,000	-
Jan 30, 2024	ng george k	bought	27,000	2.7	10,000	chief executive officer
Jan 01, 2024	young david	acquired	-	-	1,675	pres. research & development
Jan 01, 2024	bigora sian	sold (taxes)	-1,026	2.79	-368	chief development officer
Jan 01, 2024	bigora sian	acquired	-	-	1,675	chief development officer
Jan 01, 2024	young david	sold (taxes)	-1,445	2.79	-518	pres. research & development

Which funds bought or sold PCSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-14,316	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	378	378	-%
May 15, 2024	Main Street Group, LTD	new	-	235	235	-%
May 15, 2024	Coastal Bridge Advisors, LLC	sold off	-100	-21,734	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	114,941,000	114,941,000	0.07%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-400	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	10,654	10,654	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-6,249	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	56,987	56,987	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-15,000	-	-%

Are Funds Buying or Selling PCSA?

Are funds buying PCSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PCSA

No. of Funds

Unveiling Processa Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 10, 2021	manchester management co llc	0.9%	142,427	SC 13G/A
Jun 11, 2021	yuhan (usa) corp	7.3%	750,000	SC 13G
Apr 08, 2021	manchester management co llc	4.2%	648,300	SC 13G/A
Oct 13, 2020	manchester management co llc	7.4%	1e+06	SC 13G
Oct 13, 2020	young david	14.2%	1,991,168	SC 13D

Recent SEC filings of Processa Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 11, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report

Peers (Alternatives to Processa Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Processa Pharmaceuticals, Inc. News

Latest updates

Processa Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2020Q3	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2
Revenue	100.0%	197	99.00	-	-	5.00	18.00	58.00	-	38.00	1,317	53.00	113	20.00	73.00	126	97.00	19.00	34.00	49.00	97.00
Gross Profit	-	-	-	-	-	5.00	-45.31	16.00	9.00	13.00	-40.77	27.00	43.00	11.00	36.00	45.00	36.00	7.00	-	15.00	43.00
Operating Expenses	1151.2%	2,956	236	829	575	281	176	140	1,891	471	645	689	781	1,295	829	-	-	-	-	-	-
S&GA Expenses	-	423	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-	533	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	194.1%	186	63.00	63.00	63.00	56.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-Infinity%	-70.46	-	-	-	-	-25*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-3,141	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-Infinity%	-3,071	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	71.9%	9,945	5,787	8,083	10,090	12,432	8,620	18,604	21,658	24,301	26,464	29,025	31,138	33,338	25,214	9,589	10,011	10,012	10,883	10,821	11,306	12,078
Current Assets	74.0%	9,800	5,632	7,907	9,897	12,219	8,387	10,887	13,961	16,384	18,327	20,670	22,566	24,546	16,203	376	577	357	1,007	725	990	1,543
Cash Equivalents	89.5%	8,920	4,706	6,861	8,677	10,742	6,504	9,055	12,064	14,395	16,498	19,093	20,831	23,048	15,416	325	453	142	692	504	722	1,249
Net PPE	-5.4%	2.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	484*	3.00	5.00	7.00	9.00	11.00	13.00	15.00
Liabilities	33.1%	1,061	797	915	931	2,290	1,149	1,364	1,576	1,064	978	1,817	1,896	2,002	2,275	4,062	3,418	2,778	2,871	2,151	2,804	2,954
Current Liabilities	38.3%	1,011	731	826	821	2,161	999	1,193	1,571	1,058	971	1,226	1,161	1,096	1,221	2,658	1,898	1,246	1,192	292	783	725
Shareholder's Equity	78.1%	8,883	4,989	7,168	9,160	10,142	7,471	17,240	20,082	23,237	25,485	27,208	29,242	31,336	22,939	5,527	6,593	7,234	8,013	8,671	8,502	9,124
Retained Earnings	-3.6%	-78,100	-75,369	-73,000	-70,900	-68,269	-64,247	-51,235	-45,200	-40,100	-36,823	-33,600	-30,652	-27,495	-25,395	-15,661	-12,589	-11,856	-10,982	-10,207	-9,344	-8,374
Additional Paid-In Capital	8.2%	87,279	80,658	80,430	80,339	78,709	72,018	68,774	65,595	63,586	62,307	60,846	59,892	58,830	48,334	21,188	19,182	19,090	18,994	18,874	19,246	19,180
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	29.00	-	-	-	29.00	-	-	22.00	20.00	18.00	16.00	-
Shares Outstanding	122.1%	2,856	1,286	1,232	1,227	1,227	802	810	797	792	786	759	770	729	-	-	-	-	-	-	-	-
Float	-	-	-	-	10,200	-	-	-	33,800	-	-	-	95,400	-	-	-	22,000	-	-	-	44,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.8%	-2,000	-2,123	-1,739	-2,085	-2,114	-2,497	-2,974	-2,330	-1,802	-2,726	-1,552	-2,193	-2,243	-2,275	29.00	-350	-546	-613	-721	-807	-607
Share Based Compensation	-34.7%	168	257	143	319	342	2,777	3,214	2,009	829	1,120	1,114	865	308	2,373	165	94.00	99.00	116	269	66.00	59.00
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	20562.8%	6,263	-30.61	-52.75	-	6,352	-53.60	-35.25	-	-300	131	-185	-23.08	9,876	17,366	-156	661	-2.81	801	504	281	115
Buy Backs	-	-	-	-	-	-	-	-	-	300	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PCSA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses
Research and development expenses	$ 1,539,070	$ 1,627,480
General and administrative expenses	1,270,528	2,478,055
Operating Loss	(2,809,598)	(4,105,535)
Other Income (Expense), net	83,217	83,462
Net Loss	$ (2,726,381)	$ (4,022,073)
Net Loss Per Common Share - Basic	$ (1.11)	$ (3.53)
Net Loss Per Common Share - Diluted	$ (1.11)	$ (3.53)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic	2,466,523	1,138,573
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted	2,466,523	1,138,573

PCSA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 8,920,363	$ 4,706,197
Due from related parties	22,295
Prepaid expenses and other	857,635	926,300
Total Current Assets	9,800,293	5,632,497
Property and Equipment, net	2,415	2,554
Other Assets
Lease right-of-use assets, net of accumulated amortization	136,489	146,057
Security deposit	5,535	5,535
Total Other Assets	142,024	151,592
Total Assets	9,944,732	5,786,643
Current Liabilities
Current maturities of lease liabilities	89,680	83,649
Accounts payable	455,368	311,617
Due to licensor		189,000
Due to related parties		39
Accrued expenses	465,618	146,274
Total Current Liabilities	1,010,666	730,579
Non-current Liabilities
Non-current lease liabilities	50,700	66,905
Total Liabilities	1,061,366	797,484
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $0.0001, 100,000,000 shares authorized: 2,860,981 issued and 2,855,981 outstanding at March 31, 2024 and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023	286	129
Additional paid-in capital	87,278,542	80,658,111
Treasury stock at cost — 5,000 shares at March 31, 2024 and December 31, 2023	(300,000)	(300,000)
Accumulated deficit	(78,095,462)	(75,369,081)
Total Stockholders’ Equity	8,883,366	4,989,159
Total Liabilities and Stockholders’ Equity	$ 9,944,732	$ 5,786,643

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

CEO	Mr. George K. Ng Esq., J.D.
WEBSITE	processapharmaceuticals.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Processa Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Processa Pharmaceuticals, Inc.? What does PCSA stand for in stocks?

PCSA is the stock ticker symbol of Processa Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Processa Pharmaceuticals, Inc. (PCSA)?

As of Fri May 17 2024, market cap of Processa Pharmaceuticals, Inc. is 5.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCSA stock?

You can check PCSA's fair value in chart for subscribers.

What is the fair value of PCSA stock?

You can check PCSA's fair value in chart for subscribers. The fair value of Processa Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Processa Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Processa Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCSA is over valued or under valued. Whether Processa Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Processa Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCSA.

What is Processa Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PCSA's PE ratio (Price to Earnings) is -0.56 and Price to Sales (PS) ratio is 270.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCSA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Processa Pharmaceuticals, Inc.'s stock?

In the past 10 years, Processa Pharmaceuticals, Inc. has provided -0.511 (multiply by 100 for percentage) rate of return.